← Human Trials & Peer-Reviewed Studies
Effect of inhaled thiorphan, a neutral endopeptidase inhibitor, on the bronchodilator response to inhaled atrial natriuretic peptide (ANP)
Plain-language guide to PMID 8658373 (1996): double-blind randomized controlled trial study of ANP (Atrial Natriuretic Peptide).
Key Facts
- PMID
- 8658373
- Journal
- Thorax
- Year
- 1996
- Study type
- Randomized Controlled Trial
- Authors
- Angus RM et al. (4 authors)
- DOI
- 10.1136/thx.51.1.71
What This Study Did, in Plain Language
What Was Tested
Researchers studied ANP (Atrial Natriuretic Peptide) in this randomized controlled trial publication.
The hormone atrial natriuretic peptide (ANP) causes bronchodilation and partially protects against direct and indirect bronchial challenges.
It was hypothesised that pretreatment with thiorphan, an NEP inhibitor, might enhance the bronchodilator response to inhaled ANP.
Who Took Part
PubMed indexes the participants as adults and middle-aged adults, both men and women.
How the Study Was Run
The design is described as randomized, double-blind, placebo-controlled and crossover.
Because people in this ANP (Atrial Natriuretic Peptide) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.
As a double-blind ANP (Atrial Natriuretic Peptide) study, the assignments were hidden from both participants and investigators until the end.
Some participants received a placebo instead of ANP (Atrial Natriuretic Peptide), giving a reference point.
In the crossover set-up each of the participants took both ANP (Atrial Natriuretic Peptide) and the comparison in turn, acting as their own control.
Spirometric parameters were measured after each inhalation and thereafter for the next two hours.
What Was Measured
PubMed files the paper under topics including Administration, Inhalation, Albuterol, Asthma, Atrial Natriuretic Factor, Bronchodilator Agents, Drug Synergism and Forced Expiratory Volume.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of ANP (Atrial Natriuretic Peptide).
Results are reported in around 6 sentences of the abstract; we leave them to the paper itself rather than summarise them.
The publication is from 1996 (Thorax), a journal based in England.
More context: the ANP (Atrial Natriuretic Peptide) compound page, all human trials.
Our Notes on the Compound
ANP (Atrial Natriuretic Peptide): A 28-amino-acid heart hormone that relaxes blood vessels and increases salt excretion; carperitide is a recombinant form.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.